Piper Sandler analyst David Amsellem assumed coverage of AbbVie (ABBV) with an Overweight rating and $231 price target The company is in an “enviable position” as it does not face a major loss of exclusivity through the end of the decade, the analyst tells investors in a research note. Piper believes AbbVie’s visibility into continued sales and EBITDA growth through the end of the decade is high with Skyrizi and Rinvoq expansion, visibility into growth for the oncology segment, and a durable neuromodulator franchise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie: Strong Buy Rating Due to Minimal LOE Risks and Growth in Key Segments
- UnitedHealth Stock (UNH) Tumbles 50% YTD; Here’s How to Buy the Dip Without the Risk
- AbbVie’s Immunotherapy Trial: A Potential Game-Changer for Advanced Solid Tumors
- AbbVie’s Phase 1 Study on Etentamig for Multiple Myeloma: Key Insights for Investors
- AbbVie’s Duodopa Study: A Deep Dive into Parkinson’s Treatment